Centers for Disease Control and Prevention (CDC) Chronic Kidney Disease Program
To address the social and economic impact of kidney disease, NKF worked with Congress to initiate a Chronic Kidney Disease Program at CDC in FY 2006. Prior to this, no national public health program focusing on early detection and treatment of CKD existed. CKD is often asymptomatic -- especially in the early stages -- and therefore goes undetected without laboratory testing. Some people remain undiagnosed until they have reached CKD Stage 5 and must begin dialysis immediately. However, cost-effective early identification and treatment can slow the progression of kidney disease, delay complications, and prevent or delay kidney failure. NKF urges the Committee to provide $2.2 million for the CKD program for FY 2016, an increase of $100 million.
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NKF joins other members of the Friends of NIDDK to request $2.066 billion for the Institute in FY 2016. Medicare spends $87 billion annually to care for patients with kidney disease, including nearly $29 billion for individuals with ESRD, yet NIH funding for kidney disease research is only about $600 million annually.
Chronic Kidney Disease Improvement in Research and Treatment Act
NKF supports the Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 2644. This bill promotes kidney disease research and education and protects access to care for dialysis patients. This legislation would enhance current research efforts by assessing the adequacy of federal funding, identifying gaps in research and studying the progression of kidney disease and treatment of kidney failure in minorities.
Latest Updates on Kidney Disease Research Programs
9/25/17 — The National Kidney Foundation has joined with 88 other organizations in support of medical research funding. Click to see the advertisement (pdf).
9/15/17 — The National Kidney Foundation is pleased to endorse H.R. 2644, introduced by Representatives Tom Marino (R-PA), John Lewis (D-GA) and Peter Roskam (R-IL). The legislation would benefit chronic kidney disease (CKD) patients by expanding access to health insurance options, creating greater opportunities for research and innovation, increasing access to various treatment options, and improving patient care and quality outcomes. Read the full statement (PDF).
3/9/17 — NKF submitted testimony to the House Appropriations Committee's Subcommittees on Labor, HHS, Education, and Related Agencies regarding the impact of Chronic Kidney Disease (CKD), and programs Congress can further support at the National Institutes of Health, Centers for Disease Control, and Health Resources and Services Administration to improve early detection and treatment of the disease. Read the full testimony (pdf).